Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tendiren
- Development stage
- Unknown
- Lead developer
- Investigación Farmacéutica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tendiren is a multi-ingredient dietary supplement developed and manufactured by the Mexican pharmaceutical company IFA CELTICS. Formulated for metabolic health and weight management, it contains three active components: Garcinia cambogia extract, Citrus aurantium (bitter orange) extract, and chromium polynicotinate. The product functions through a combination of mechanisms: Garcinia cambogia provides hydroxycitric acid (HCA), which inhibits ATP citrate lyase to reduce fatty acid synthesis; Citrus aurantium contains synephrine, which acts as a thermogenic agent via adrenergic receptors; and chromium polynicotinate enhances insulin sensitivity to improve glucose metabolism. It is available in oral tablet form and is primarily indicated for the treatment of obesity and metabolic support.
- Brand names
- TendirenTendiren-IFA CELTICS
- Other names
- Garcinia cambogia + Citrus aurantium + chromium polynicotinate
02
Targets
ACLY (ATP-citrate synthase)ADRB3 (β3)INSR (Insulin receptor)
Beyond the preview
Go deeper on Tendiren.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tendiren.